Belantamab mafodotin, bortezomib, dexamethasone triplet scores big in RRMM
Triplet therapy with belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improves outcomes in relapsed or refractory multiple myeloma (RRMM), outperforming the daratumumab, bortezomib, and dexamethasone (DVd) combination therapy, according to the second interim analysis of the phase III DREAMM-7 trial.